リシノプリルの世界市場レポート 2025年

リシノプリル市場規模は、今後数年間で力強い成長が見込まれます。2029年にはCAGR6.3％で24億米ドルに成長します。予測期間の成長は、高血圧と心血管疾患の有病率の上昇、ジェネリック医薬品と費用対効果、意識の高まりと早期診断、効果的な治療に対する需要の高まり、高齢化などに起因すると考えられます。予測期間における主な動向としては、ドラッグデリバリーの革新、患者中心のドラッグデリバリーアプローチの強化の必要性、費用対効果の高いソリューションへの需要、心不全に対する効果的な治療への需要、糖尿病性腎臓病に対する効果的な治療への需要などが挙げられます。

心血管疾患の有病率の増加は、今後のリシノプリル市場の成長を促進すると予想されます。心血管疾患（CVD）とは、心臓や血管に影響を及ぼすさまざまな疾患を指します。これらの疾患の罹患率の上昇は、人口増加、高齢化、危険因子、効果的な予防・治療戦略の不十分な実施などの要因に起因しています。リシノプリルは、主に血圧を下げ、心臓や腎臓への負担を軽減することで、心血管疾患の管理に役立ちます。アンジオテンシンⅡの産生を抑制し、血管の拡張を促し、血液量を減らし、臓器を障害から守ることで効果を発揮します。例えば、2024年5月、シンガポールに本部を置く非営利団体であるシンガポール心臓財団（SHF）は、虚血性心疾患による死亡者数が5,302人と報告し、2022年の5,290人から微増しています。したがって、心血管疾患の有病率の増加がリシノプリル市場の成長を促進しています。

高血圧の有病率の増加がリシノプリル市場を押し上げると予想されます。高血圧は、動脈壁に対する血液の力が常に高すぎる状態です。不健康な食生活、座りがちなライフスタイル、高齢化、長期的なストレスなどの要因が、高血圧の有病率上昇に寄与しています。リシノプリルは、アンジオテンシンIIの形成を阻害することによって高血圧を効果的に管理し、血管の弛緩、血液量の減少、血圧の低下をもたらします。例えば、世界保健機関（WHO）は2023年3月、世界の30～79歳の成人約12億8,000万人が高血圧症であると報告しました。したがって、高血圧の有病率の増加がリシノプリル市場を牽引しています。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場- 金利、インフレ、地政学、新型コロナウイルス感染症、そして景気回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界リシノプリルPESTEL分析（政治、社会、技術、環境、法的要因、促進要因と抑制要因）
• 最終用途産業の分析
• 世界のリシノプリル市場：成長率分析
• 世界のリシノプリル市場の実績：規模と成長, 2019-2024
• 世界のリシノプリル市場の予測：規模と成長, 2024-2029, 2034F
• 世界リシノプリル総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界のリシノプリル市場ブランド別、実績と予測, 2019-2024, 2024-2029F, 2034F
• ゼストレティック
• プリンビル
• ゼストリル
• その他のブランド
• 世界のリシノプリル市場：疾患別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 高血圧
• 心不全
• 心臓発作
• ストローク
• 糖尿病性腎臓病
• その他の病気
• 世界のリシノプリル市場投与量別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 錠剤
• 液体
• その他の投与量
• 世界のリシノプリル市場人口タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 子供たち
• 大人
• 世界のリシノプリル市場：エンドユーザー別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 病院
• 専門クリニック
• その他のエンドユーザー
• 世界のリシノプリル市場ゼストレティックのサブセグメンテーション（タイプ別）、実績と予測, 2019-2024, 2024-2029F, 2034F
• さまざまな剤形
• ゼストレティックのジェネリック医薬品
• 世界のリシノプリル市場、プリンビルの種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• さまざまな剤形
• プリンビルのジェネリック医薬品
• 世界のリシノプリル市場ゼストリルのサブセグメンテーション（タイプ別）、実績と予測, 2019-2024, 2024-2029F, 2034F
• さまざまな剤形
• ゼストリルのジェネリック医薬品
• 世界のリシノプリル市場、その他のブランドのタイプ別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 国際ブランドのバリエーション
• 複合医薬品製剤

第7章 地域別・国別分析

• 世界のリシノプリル市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 世界のリシノプリル市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• リシノプリル市場：競合情勢
• リシノプリル市場：企業プロファイル
  • Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
  • AstraZeneca Plc Overview, Products and Services, Strategy and Financial Analysis
  • Vitaris Inc. Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• Teva Pharmaceutical Industries Limited
• Bausch Health Companies Inc.
• Hetero Ltd.
• Sun Pharmaceutical Industries Limited
• Aurobindo Pharma Ltd.
• Cipla Inc.
• Hikma Pharmaceutical Plc
• Apotex Inc.
• Amneal Pharmaceutical Inc.
• Lupin Ltd.
• Zhejiang Huahai Pharmaceutical Co. Ltd.
• Metrochem API Private Limited
• Calyx Chemicals & Pharmaceuticals Limited
• Farmhispania Group
• Zydus Cadila Healthcare Ltd.

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• リシノプリル市場2029：新たな機会を提供する国
• リシノプリル市場2029：新たな機会を提供するセグメント
• リシノプリル市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Lisinopril is a medication classified as an angiotensin-converting enzyme (ACE) inhibitor. It works by reducing certain chemicals that tighten blood vessels, facilitating smoother blood flow and improving the heart's pumping efficiency. Lisinopril is prescribed for adults to treat congestive heart failure and to increase survival rates after a heart attack.

The main brands of lisinopril include Zestoretic, Prinivil, Zestril, among others. Zestoretic is a combination medication containing lisinopril, an ACE inhibitor, and hydrochlorothiazide, a thiazide diuretic. It is used to treat conditions such as hypertension, heart failure, heart attacks, strokes, diabetic kidney disease, among others. It is available in various forms such as tablets and liquid, and is prescribed to different populations including children and adults. These medications are used by various end-users such as hospitals, specialty clinics, and others.

The lisinopril market research report is one of a series of new reports from The Business Research Company that provides lisinopril market statistics, including lisinopril industry global market size, regional shares, competitors with a lisinopril market share, detailed lisinopril market segments, market trends, and opportunities, and any further data you may need to thrive in the lisinopril industry. This lisinopril market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The lisinopril market size has grown strongly in recent years. It will grow from $1.76 billion in 2024 to $1.88 billion in 2025 at a compound annual growth rate (CAGR) of 6.7%. The growth in the historic period can be attributed to increased accessibility, lifestyle shifts, increased screening programs, increased accessibility of generic lisinopril, and increased patient adherence.

The lisinopril market size is expected to see strong growth in the next few years. It will grow to $2.4 billion in 2029 at a compound annual growth rate (CAGR) of 6.3%. The growth in the forecast period can be attributed to rising prevalence of hypertension and cardiovascular diseases, generic versions and cost-effectiveness, growing awareness and early diagnosis, growing demand for effective treatments, and aging population. Major trends in the forecast period include innovations in drug delivery, need for enhanced and patient-centric drug delivery approaches, demand for cost-effective solutions, demand for effective treatments for heart failure, and demand for effective treatments for diabetic kidney disease.

The increasing prevalence of cardiovascular diseases is expected to drive the growth of the lisinopril market in the future. Cardiovascular diseases (CVDs) refer to a variety of conditions that affect the heart and blood vessels. The rising incidence of these diseases can be attributed to factors such as population growth, aging, risk factors, and the inadequate implementation of effective prevention and treatment strategies. Lisinopril aids in managing cardiovascular diseases primarily by lowering blood pressure and reducing the strain on the heart and kidneys. It works by inhibiting the production of angiotensin II, promoting blood vessel dilation, reducing blood volume, and protecting organs from damage. For example, in May 2024, the Singapore Heart Foundation (SHF), a non-profit organization based in Singapore, reported 5,302 deaths from ischemic heart diseases, a slight increase from 5,290 deaths in 2022. Therefore, the growing prevalence of cardiovascular diseases is fueling the growth of the lisinopril market.

The growing prevalence of hypertension is expected to boost the lisinopril market. Hypertension, or high blood pressure, is a condition where the force of blood against artery walls is consistently too high. Factors such as an unhealthy diet, sedentary lifestyle, aging population, and long-term stress contribute to the increasing prevalence of hypertension. Lisinopril effectively manages hypertension by blocking the formation of angiotensin II, leading to blood vessel relaxation, reduced blood volume, and lower blood pressure. For instance, the World Health Organization reported in March 2023 that around 1.28 billion adults aged 30-79 worldwide had hypertension. Therefore, the increasing prevalence of hypertension is driving the lisinopril market.

In January 2024, Sun Pharmaceutical Industries Limited, an Indian pharmaceutical company, acquired Taro Pharmaceutical Industries Ltd for $347.73 million. This acquisition allows Sun Pharma to expand its portfolio by incorporating Taro's expertise in generic and specialty medicines, active pharmaceutical ingredients (APIs), and over-the-counter products. Taro Pharmaceutical Industries Ltd, a US-based company, offers lisinopril.

Major companies operating in the lisinopril market are Merck & Co. Inc., Pfizer Inc., AbbVie Inc., AstraZeneca Plc, Vitaris Inc., Teva Pharmaceutical Industries Limited, Bausch Health Companies Inc., Hetero Ltd., Sun Pharmaceutical Industries Limited, Aurobindo Pharma Ltd., Cipla Inc., Hikma Pharmaceutical Plc, Apotex Inc., Amneal Pharmaceutical Inc., Lupin Ltd., Zhejiang Huahai Pharmaceutical Co. Ltd., Metrochem API Private Limited, Calyx Chemicals & Pharmaceuticals Limited, Farmhispania Group, Zydus Cadila Healthcare Ltd., Qingdao Qingmei Biotech Co. Ltd., LGM Pharma LLC, Amara Labs Pvt., Sms Lifesciences

North America was the largest region in the lisinopril market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the lisinopril market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the lisinopril market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The lisinopril market consists of sales of prinivil, qbrelis, zestoretic, zestril and apo-lisinopril. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Lisinopril Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on lisinopril market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for lisinopril ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The lisinopril market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Brand: Zestoretic; Prinivil; Zestril; Other Brands
• 2) By Disease: Hypertension; Heart Failure; Heart Attack; Strokes; Diabetic Kidney Disease; Other Diseases
• 3) By Dosage: Tablet; Liquid; Other Dosages
• 4) By Population Type: Children; Adults
• 5) By End-Users: Hospitals; Specialty Clinics; Other End-Users
• Subsegments:
• 1) By Zestoretic: Different Dosage Forms; Generic Versions Of Zestoretic
• 2) By Prinivil: Different Dosage Forms; Generic Versions Of Prinivil
• 3) By Zestril: Different Dosage Forms; Generic Versions Of Zestril
• 4) By Other Brands: International Brand Variants; Combination Drug Formulations
• Companies Mentioned: Merck & Co. Inc.; Pfizer Inc.; AbbVie Inc.; AstraZeneca Plc; Vitaris Inc.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Lisinopril Market Characteristics

3. Lisinopril Market Trends And Strategies

4. Lisinopril Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Covid And Recovery On The Market

5. Global Lisinopril Growth Analysis And Strategic Analysis Framework

• 5.1. Global Lisinopril PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Lisinopril Market Growth Rate Analysis
• 5.4. Global Lisinopril Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Lisinopril Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Lisinopril Total Addressable Market (TAM)

6. Lisinopril Market Segmentation

• 6.1. Global Lisinopril Market, Segmentation By Brand, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Zestoretic
• Prinivil
• Zestril
• Other Brands
• 6.2. Global Lisinopril Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hypertension
• Heart Failure
• Heart Attack
• Strokes
• Diabetic Kidney Disease
• Other Diseases
• 6.3. Global Lisinopril Market, Segmentation By Dosage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Tablet
• Liquid
• Other Dosages
• 6.4. Global Lisinopril Market, Segmentation By Population Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Children
• Adults
• 6.5. Global Lisinopril Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospitals
• Specialty Clinics
• Other End-Users
• 6.6. Global Lisinopril Market, Sub-Segmentation Of Zestoretic, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Different Dosage Forms
• Generic Versions Of Zestoretic
• 6.7. Global Lisinopril Market, Sub-Segmentation Of Prinivil, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Different Dosage Forms
• Generic Versions Of Prinivil
• 6.8. Global Lisinopril Market, Sub-Segmentation Of Zestril, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Different Dosage Forms
• Generic Versions Of Zestril
• 6.9. Global Lisinopril Market, Sub-Segmentation Of Other Brands, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• International Brand Variants
• Combination Drug Formulations

7. Lisinopril Market Regional And Country Analysis

• 7.1. Global Lisinopril Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Lisinopril Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Lisinopril Market

• 8.1. Asia-Pacific Lisinopril Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Lisinopril Market, Segmentation By Brand, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Lisinopril Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Lisinopril Market, Segmentation By Dosage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Lisinopril Market

• 9.1. China Lisinopril Market Overview
• 9.2. China Lisinopril Market, Segmentation By Brand, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Lisinopril Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Lisinopril Market, Segmentation By Dosage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Lisinopril Market

• 10.1. India Lisinopril Market, Segmentation By Brand, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Lisinopril Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Lisinopril Market, Segmentation By Dosage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Lisinopril Market

• 11.1. Japan Lisinopril Market Overview
• 11.2. Japan Lisinopril Market, Segmentation By Brand, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Lisinopril Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Lisinopril Market, Segmentation By Dosage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Lisinopril Market

• 12.1. Australia Lisinopril Market, Segmentation By Brand, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Lisinopril Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Lisinopril Market, Segmentation By Dosage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Lisinopril Market

• 13.1. Indonesia Lisinopril Market, Segmentation By Brand, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Lisinopril Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Lisinopril Market, Segmentation By Dosage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Lisinopril Market

• 14.1. South Korea Lisinopril Market Overview
• 14.2. South Korea Lisinopril Market, Segmentation By Brand, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Lisinopril Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Lisinopril Market, Segmentation By Dosage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Lisinopril Market

• 15.1. Western Europe Lisinopril Market Overview
• 15.2. Western Europe Lisinopril Market, Segmentation By Brand, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Lisinopril Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Lisinopril Market, Segmentation By Dosage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Lisinopril Market

• 16.1. UK Lisinopril Market, Segmentation By Brand, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Lisinopril Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Lisinopril Market, Segmentation By Dosage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Lisinopril Market

• 17.1. Germany Lisinopril Market, Segmentation By Brand, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Lisinopril Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Lisinopril Market, Segmentation By Dosage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Lisinopril Market

• 18.1. France Lisinopril Market, Segmentation By Brand, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Lisinopril Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Lisinopril Market, Segmentation By Dosage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Lisinopril Market

• 19.1. Italy Lisinopril Market, Segmentation By Brand, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Lisinopril Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Lisinopril Market, Segmentation By Dosage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Lisinopril Market

• 20.1. Spain Lisinopril Market, Segmentation By Brand, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Lisinopril Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Lisinopril Market, Segmentation By Dosage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Lisinopril Market

• 21.1. Eastern Europe Lisinopril Market Overview
• 21.2. Eastern Europe Lisinopril Market, Segmentation By Brand, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Lisinopril Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Lisinopril Market, Segmentation By Dosage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Lisinopril Market

• 22.1. Russia Lisinopril Market, Segmentation By Brand, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Lisinopril Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Lisinopril Market, Segmentation By Dosage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Lisinopril Market

• 23.1. North America Lisinopril Market Overview
• 23.2. North America Lisinopril Market, Segmentation By Brand, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Lisinopril Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Lisinopril Market, Segmentation By Dosage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Lisinopril Market

• 24.1. USA Lisinopril Market Overview
• 24.2. USA Lisinopril Market, Segmentation By Brand, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Lisinopril Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Lisinopril Market, Segmentation By Dosage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Lisinopril Market

• 25.1. Canada Lisinopril Market Overview
• 25.2. Canada Lisinopril Market, Segmentation By Brand, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Lisinopril Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Lisinopril Market, Segmentation By Dosage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Lisinopril Market

• 26.1. South America Lisinopril Market Overview
• 26.2. South America Lisinopril Market, Segmentation By Brand, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Lisinopril Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Lisinopril Market, Segmentation By Dosage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Lisinopril Market

• 27.1. Brazil Lisinopril Market, Segmentation By Brand, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Lisinopril Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Lisinopril Market, Segmentation By Dosage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Lisinopril Market

• 28.1. Middle East Lisinopril Market Overview
• 28.2. Middle East Lisinopril Market, Segmentation By Brand, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Lisinopril Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Lisinopril Market, Segmentation By Dosage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Lisinopril Market

• 29.1. Africa Lisinopril Market Overview
• 29.2. Africa Lisinopril Market, Segmentation By Brand, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Lisinopril Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Lisinopril Market, Segmentation By Dosage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Lisinopril Market Competitive Landscape And Company Profiles

• 30.1. Lisinopril Market Competitive Landscape
• 30.2. Lisinopril Market Company Profiles
  • 30.2.1. Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. AstraZeneca Plc Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Vitaris Inc. Overview, Products and Services, Strategy and Financial Analysis

31. Lisinopril Market Other Major And Innovative Companies

• 31.1. Teva Pharmaceutical Industries Limited
• 31.2. Bausch Health Companies Inc.
• 31.3. Hetero Ltd.
• 31.4. Sun Pharmaceutical Industries Limited
• 31.5. Aurobindo Pharma Ltd.
• 31.6. Cipla Inc.
• 31.7. Hikma Pharmaceutical Plc
• 31.8. Apotex Inc.
• 31.9. Amneal Pharmaceutical Inc.
• 31.10. Lupin Ltd.
• 31.11. Zhejiang Huahai Pharmaceutical Co. Ltd.
• 31.12. Metrochem API Private Limited
• 31.13. Calyx Chemicals & Pharmaceuticals Limited
• 31.14. Farmhispania Group
• 31.15. Zydus Cadila Healthcare Ltd.

32. Global Lisinopril Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Lisinopril Market

34. Recent Developments In The Lisinopril Market

35. Lisinopril Market High Potential Countries, Segments and Strategies

• 35.1 Lisinopril Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Lisinopril Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Lisinopril Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer